Biomaterial Database

Pyrazinamide-induced sideroblastic anemia. 2012

Giuseppe Colucci, and Tobias Silzle, and Max Solenthaler

Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland. giuseppe.colucci@insel.ch

UI	MeSH Term	Description	Entries
D007538	Isoniazid	Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.	Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D011718	Pyrazinamide	A pyrazine that is used therapeutically as an antitubercular agent.	Tisamid
D011736	Pyridoxine	The 4-methanol form of VITAMIN B 6 which is converted to PYRIDOXAL PHOSPHATE which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. Although pyridoxine and Vitamin B 6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading (EE Snell; Ann NY Acad Sci, vol 585 pg 1, 1990).	Pyridoxin,Pyridoxine Hydrochloride,Pyridoxol,Pyridoxol Hydrochloride,Rodex
D011804	Quinolines
D001853	Bone Marrow	The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.	Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D004359	Drug Therapy, Combination	Therapy with two or more separate preparations given for a combined effect.	Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004977	Ethambutol	An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)	Dexambutol,EMB-Fatol,EMB-Hefa,Etambutol Llorente,Ethambutol Hydrochloride,Etibi,Miambutol,Myambutol,EMB Fatol,EMB Hefa,Hydrochloride, Ethambutol,Llorente, Etambutol
D005260	Female		Females
D006461	Hemolysis	The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	Haemolysis,Extravascular Hemolysis,Intravascular Hemolysis,Extravascular Hemolyses,Haemolyses,Hemolyses, Extravascular,Hemolyses, Intravascular,Hemolysis, Extravascular,Hemolysis, Intravascular,Intravascular Hemolyses

Related Publications

Giuseppe Colucci, and Tobias Silzle, and Max Solenthaler

Pyrazinamide-induced sideroblastic anaemia.

August 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,

Giuseppe Colucci, and Tobias Silzle, and Max Solenthaler

Reversible sideroblastic anemia caused by pyrazinoic acid (Pyrazinamide).

June 1966, Annals of internal medicine,

Giuseppe Colucci, and Tobias Silzle, and Max Solenthaler

Thrombocytopenia and sideroblastic anemia with pyrazinoic acid amide (pyrazinamide) therapy.

April 1970, Chest,

Giuseppe Colucci, and Tobias Silzle, and Max Solenthaler

Busulfan-induced sideroblastic anemia.

July 1988, American journal of hematology,

Giuseppe Colucci, and Tobias Silzle, and Max Solenthaler

Dolutegravir-induced severe sideroblastic anemia.

June 2024, AIDS (London, England),